Boothbay Fund Management LLC Trims Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Boothbay Fund Management LLC lessened its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 43.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 156,403 shares of the company's stock after selling 119,160 shares during the period. Boothbay Fund Management LLC owned approximately 0.41% of Tarsus Pharmaceuticals worth $8,660,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of TARS. Lord Abbett & CO. LLC boosted its stake in shares of Tarsus Pharmaceuticals by 115.2% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock valued at $70,873,000 after purchasing an additional 685,111 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Tarsus Pharmaceuticals by 2,088.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock valued at $14,477,000 after purchasing an additional 420,057 shares in the last quarter. Gilder Gagnon Howe & Co. LLC boosted its position in Tarsus Pharmaceuticals by 5,636.3% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 404,237 shares of the company's stock valued at $22,383,000 after buying an additional 397,190 shares during the period. Jennison Associates LLC boosted its position in Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock valued at $138,432,000 after buying an additional 321,552 shares during the period. Finally, Invesco Ltd. boosted its position in Tarsus Pharmaceuticals by 36.7% during the 4th quarter. Invesco Ltd. now owns 932,115 shares of the company's stock valued at $51,611,000 after buying an additional 250,018 shares during the period. Hedge funds and other institutional investors own 90.01% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on TARS shares. Guggenheim reissued a "buy" rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Jefferies Financial Group increased their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Barclays dropped their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Oppenheimer upped their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Finally, HC Wainwright restated a "buy" rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $63.67.

Tarsus Pharmaceuticals Stock Down 3.2 %

NASDAQ TARS traded down $1.66 during mid-day trading on Thursday, reaching $50.25. The stock had a trading volume of 350,018 shares, compared to its average volume of 692,374. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28. The stock has a market cap of $1.93 billion, a PE ratio of -13.20 and a beta of 0.94. The company has a fifty day moving average price of $47.73 and a 200 day moving average price of $48.57. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million. On average, research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 7,131 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.99. Following the completion of the sale, the chief executive officer now directly owns 70,720 shares in the company, valued at approximately $3,273,628.80. The trade was a 9.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dianne C. Whitfield sold 2,315 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $107,161.35. Following the sale, the insider now owns 50,751 shares of the company's stock, valued at approximately $2,349,263.79. This represents a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock worth $1,581,173 in the last three months. Insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.